Company intelligence / Profile preview

Potentia Pharmaceuticals

Crestwood, Kentucky, United Statesbiospace.com ↗

Ownership: Private
Employees: ~1
Development stage: Phase 1

Overview

Potentia Pharmaceuticals developed the first complement inhibitor for ophthalmological use, targeting age-related macular degeneration. Its lead compound POT‑4 completed a Phase I trial showing safety and tolerability with no serious adverse events. The company’s science supported further clinical development into Phase II trials before its programs were acquired by Apellis Pharmaceuticals.

Therapeutic areas: OphthalmologyHematology
Modalities: Peptide therapeutics (complement inhibitors, specifically compstatin derivatives such as POT-4/APL‑1)
Industry: Biotech

Drug pipeline

1 asset

POT-4

Phase 1

Indications: Age-related macular degeneration

Partnerships

Alcon—licensed ocular program to Alcon in October 2009 with purchase option agreement for further development of POT–4; partnership ended prior to Apellis acquisition.

Beyond the preview

Go deeper on Potentia Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potentia Pharmaceuticals.

Explore the full profile